Latest news with #Arexvy
Medscape
14-07-2025
- Health
- Medscape
How a Shingles Shot May Guard Against Dementia
New evidence suggests that AS01-based vaccines, beyond their established role in preventing shingles and respiratory syncytial virus (RSV), may also reduce the risk for dementia. The supportive data, published on June 25 in the journal npj Vaccines, underscores the importance of maintaining up-to-date immunizations, particularly among older adults. 1. Dementia risk dropped after AS01 vaccines. Patients who received the shingles (Shingrix) or RSV (Arexvy) vaccines — both containing the AS01 adjuvant — had a significantly lower risk for dementia over 18 months compared to those who received the flu vaccine, with an 18% lower dementia diagnosis rate for shingles vaccine and a 29% lower rate for RSV vaccine. 2. Even greater protection when both vaccines were used. Receiving both AS01 vaccines was linked to a 37% reduced dementia risk, suggesting a possible additive effect. 3. It's the adjuvant, not the vaccine itself. The consistent protective signal observed in both shingles and RSV vaccine populations points to the AS01 adjuvant as the probable key factor. 4. What's in AS01? A powerful immune combo. The adjuvant includes MPL and QS-21, known to affect brain inflammation and Alzheimer's-related alterations. MPL stimulates immune cells, while QS-21 enhances the immune response. 5. More research needed, but promising. Experts stress that these are observational data and short-term, but the research adds weight to the growing case for broader vaccine benefits, including possible brain protection. Bottom line: While it's too early to change clinical practice, these findings hint that adjuvanted vaccines like Shingrix and Arexvy may do more than prevent infections; they might help guard against dementia, too.
South Wales Guardian
07-07-2025
- Health
- South Wales Guardian
Regulator warns of small risk of serious condition in people having RSV jab
Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing. It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over. However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'. In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.' It warned staff to be alert to the signs and symptoms of the syndrome. It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy. The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill. RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays. The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women. The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints. There may also be problems breathing and drooping face muscles or trouble swallowing or speaking. Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo. This is in the context of over 1.9 million doses of Abrysvo administered, it said. Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date. In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Glasgow Times
07-07-2025
- Health
- Glasgow Times
Regulator warns of small risk of serious condition in people having RSV jab
Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing. It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over. However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'. In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.' It warned staff to be alert to the signs and symptoms of the syndrome. It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy. The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill. RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays. The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women. The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints. There may also be problems breathing and drooping face muscles or trouble swallowing or speaking. Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo. This is in the context of over 1.9 million doses of Abrysvo administered, it said. Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date. In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Rhyl Journal
07-07-2025
- Health
- Rhyl Journal
Regulator warns of small risk of serious condition in people having RSV jab
Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing. It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over. However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'. In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.' It warned staff to be alert to the signs and symptoms of the syndrome. It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy. The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill. RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays. The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women. The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints. There may also be problems breathing and drooping face muscles or trouble swallowing or speaking. Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo. This is in the context of over 1.9 million doses of Abrysvo administered, it said. Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date. In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
North Wales Chronicle
07-07-2025
- Health
- North Wales Chronicle
Regulator warns of small risk of serious condition in people having RSV jab
Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing. It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over. However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'. In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.' It warned staff to be alert to the signs and symptoms of the syndrome. It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy. The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill. RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays. The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women. The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK. Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints. There may also be problems breathing and drooping face muscles or trouble swallowing or speaking. Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo. This is in the context of over 1.9 million doses of Abrysvo administered, it said. Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date. In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
